公司資料
Madrigal 股價、新聞與催化劑
- 股票代碼:
- MDGL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
524.87 USD (+3.41%)
收盤價
最後更新: 2026年8月17日
10.4B USD
市值
股價為何變動
As of Aug 17, 2026, MDGL closed up 3.41% at $524.87. No new same-company headline was identified in the current news window.
公司概覽
Commercial MASH Leader
Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis.
Rezdiffra Growth Platform
Rezdiffra is the company's commercial foundation. Second-quarter 2026 net sales reached $364.3 million, up 71% year over year, and more than 49,000 patients were on therapy as of June 30, 2026. Madrigal is investing in field-force expansion, disease education, real-world evidence, and physician adoption to maximize the long-term value of the launch.
Pipeline Anchored by Combination Therapy
Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative. The company initiated Phase 1 dosing in June 2026 as part of a strategy to develop once-daily oral combination treatments for MASH anchored by Rezdiffra.
Strategic Position
Madrigal is best understood as a commercial-stage MASH company with a foundational therapy and a strategy to defend leadership through IP, evidence generation, and combination development. Its differentiation rests on Rezdiffra's first-mover position, expanding patient base, and potential to address both liver and cardiometabolic risk.
未來催化劑
- Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
- Future data from the Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。